Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.
Astrazeneca has scored a hit with Imfinzi in the Caspian trial, but the results are unlikely to endanger Roche's Tecentriq.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Adding immunotherapy to targeted drugs could improve responses in some metastatic melanomas. Two pending pivotal trials will show whether the increased toxicity is worth…
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.